Most BCs (60–80%) are positive for ER and PGR expression and ER-positive (ER+) BC patients show an improved response to anti-estrogen-based therapies, have longer survival and are less likely to develop recurrent diseases as compared to ER-negative or ER-negative/PGR-negative BC patients [42,43]. Here, ESR1 is linked to breast cancer.